Are the new guidelines for the use of lipid-lowering agents sound, and should their adoption be encouraged?
出版信息
Can J Hosp Pharm. 2014 May;67(3):246-9. doi: 10.4212/cjhp.v67i3.1363.
Abstract
摘要
相似文献
1
Are the new guidelines for the use of lipid-lowering agents sound, and should their adoption be encouraged?降脂药物使用的新指南合理吗？是否应该鼓励采用这些指南？
Can J Hosp Pharm. 2014 May;67(3):246-9. doi: 10.4212/cjhp.v67i3.1363.
2
Lipid lowering and coronary heart disease risk: how appropriate are the national guidelines?降脂与冠心病风险：国家指南的适用性如何？
Med J Aust. 2001 Nov 5;175(9):471-5. doi: 10.5694/j.1326-5377.2001.tb143679.x.
3
Comparison of the European and US guidelines for lipid-lowering therapy in primary prevention of cardiovascular disease.比较欧洲和美国指南中的降脂治疗方案在心血管疾病一级预防中的应用。
Eur J Prev Cardiol. 2023 Nov 30;30(17):1856-1864. doi: 10.1093/eurjpc/zwad193.
4
A Clinical Guide to Combination Lipid-Lowering Therapy.《联合降脂治疗临床指南》
Curr Atheroscler Rep. 2018 Mar 7;20(4):19. doi: 10.1007/s11883-018-0721-2.
5
Use of lipid-lowering agents in rheumatoid arthritis: a population-based cohort study.在类风湿关节炎中使用降脂药物：一项基于人群的队列研究。
J Rheumatol. 2013 Jul;40(7):1082-8. doi: 10.3899/jrheum.121302. Epub 2013 May 1.
6
[Lipid-lowering therapy in patients with coronary disease: proportion of patients requiring treatment according to recommendations of the Swiss Society of Cardiology].
Schweiz Med Wochenschr. 1999 Dec 18;129(50):1959-63.
7
Lipid-lowering medication for secondary prevention of coronary heart disease in a German outpatient population: the gap between treatment guidelines and real life treatment patterns.德国门诊患者中用于冠心病二级预防的降脂药物：治疗指南与实际治疗模式之间的差距。
Prev Med. 2002 Jul;35(1):48-53. doi: 10.1006/pmed.2002.1050.
8
[Guidelines for lowering lipids are too infrequently observed. Results of a retrospective study of coronary heart disease patients].[降低血脂的指南很少得到遵循。一项冠心病患者回顾性研究的结果]
MMW Fortschr Med. 2000 Aug 31;142(35):35-7.
9
Prescription of lipid-lowering medications for patients with type 2 diabetes mellitus and risk-associated LDL cholesterol: a nationwide study of guideline adherence from the Swedish National Diabetes Register.2型糖尿病患者及伴有风险的低密度脂蛋白胆固醇患者的降脂药物处方：一项基于瑞典国家糖尿病登记处的全国性指南依从性研究
BMC Health Serv Res. 2018 Nov 28;18(1):900. doi: 10.1186/s12913-018-3707-4.
10
How do the Australian guidelines for lipid-lowering drugs perform in practice? Cardiovascular disease risk in the AusDiab Study, 1999-2000.澳大利亚降血脂药物指南在实际应用中表现如何？1999 - 2000年澳大利亚糖尿病研究中的心血管疾病风险。
Med J Aust. 2008 Sep 15;189(6):319-22. doi: 10.5694/j.1326-5377.2008.tb02049.x.
引用本文的文献
1
[Not Available].[无可用内容]
Can J Hosp Pharm. 2014 May;67(3):186-7.
2
Can I get a guideline to help me interpret treatment guidelines?我能得到一份帮助我解读治疗指南的指南吗？
Can J Hosp Pharm. 2014 May;67(3):181-2. doi: 10.4212/cjhp.v67i3.1353.
本文引用的文献
1
Are the ACC/AHA guidelines on the treatment of blood cholesterol a game changer? A perspective from the Canadian Cardiovascular Society Dyslipidemia Panel.美国心脏病学会/美国心脏协会关于血液胆固醇治疗的指南是否改变了局面？来自加拿大心血管学会血脂异常小组的观点。
Can J Cardiol. 2014 Apr;30(4):377-80. doi: 10.1016/j.cjca.2014.01.009. Epub 2014 Jan 17.
2
More than a billion people taking statins?: Potential implications of the new cardiovascular guidelines.超过十亿人服用他汀类药物？：新心血管指南的潜在影响。
JAMA. 2014 Feb 5;311(5):463-4. doi: 10.1001/jama.2013.284657.
3
Statins: new American guidelines for prevention of cardiovascular disease.他汀类药物：美国预防心血管疾病的新指南
Lancet. 2013 Nov 30;382(9907):1762-5. doi: 10.1016/S0140-6736(13)62388-0. Epub 2013 Nov 20.
4
2012 update of the Canadian Cardiovascular Society guidelines for the diagnosis and treatment of dyslipidemia for the prevention of cardiovascular disease in the adult.2012 年加拿大心血管学会血脂异常诊断和治疗指南更新：预防成年人心血管疾病。
Can J Cardiol. 2013 Feb;29(2):151-67. doi: 10.1016/j.cjca.2012.11.032.
5
Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study.血浆高密度脂蛋白胆固醇与心肌梗死风险：一项孟德尔随机化研究。
Lancet. 2012 Aug 11;380(9841):572-80. doi: 10.1016/S0140-6736(12)60312-2. Epub 2012 May 17.
6
Use of global coronary heart disease risk assessment in practice: a cross-sectional survey of a sample of U.S. physicians.在实践中使用全球冠心病风险评估：对美国医生样本的横断面调查。
BMC Health Serv Res. 2012 Jan 24;12:20. doi: 10.1186/1472-6963-12-20.
7
ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS).ESC/EAS 血脂异常管理指南：欧洲心脏病学会（ESC）和欧洲动脉粥样硬化学会（EAS）血脂异常管理工作组
Eur Heart J. 2011 Jul;32(14):1769-818. doi: 10.1093/eurheartj/ehr158. Epub 2011 Jun 28.
8
Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials.更强化降低 LDL 胆固醇的疗效和安全性：来自 26 项随机试验中 170000 名参与者数据的荟萃分析。
Lancet. 2010 Nov 13;376(9753):1670-81. doi: 10.1016/S0140-6736(10)61350-5. Epub 2010 Nov 8.
9
Optimizing statin treatment for primary prevention of coronary artery disease.优化他汀类药物治疗以预防冠心病
Ann Intern Med. 2010 Jan 19;152(2):69-77. doi: 10.7326/0003-4819-152-2-201001190-00004.
10
The relative merits of population-based and targeted prevention strategies.基于人群的预防策略和针对性预防策略的相对优点。
Milbank Q. 2008 Dec;86(4):557-80. doi: 10.1111/j.1468-0009.2008.00534.x.
Zotero 插件